Edwards Stays On Track For ‘Mid-Teens’ TAVR Growth In 2021
Edwards Lifesciences reported $1.2bn in sales in the first quarter of 2021, up 5% year-over-year and exceeding the projections the company offered three months ago.
You may also be interested in...
Fourth-quarter sales of Edwards Sapien transcatheter aortic valve systems grew 2% year-over-year overall, despite the intense challenges created by COVID-19.
Medicare now covers transcatheter edge-to-edge repair for both functional and degenerative mitral regurgitation under specific conditions.
The company stopped shipping Alaris in early 2020 after the FDA requested a new 510(k) for modifications and the device has been the subject of several recalls since then.